Shilpa Medicare arm gets 1 UFSDA observation for Raichur Unit
Karnataka: Shilpa Medicare has announced that the United States Food and Drugs Administration (USFDA) has concluded an inspection with one observation at Unit-1 of Shilpa Pharma Lifesciences Limited, a wholly owned subsidiary of the Company located at Raichur.
The facility was inspected from March 3-7, 2025.
"On conclusion of inspection, we received 1 (one) observation in form 483, which is procedural in nature," the Company stated.
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts
"The company will closely work with the agency and remain committed to address this observation comprehensively within stipulated time," Shilpa Medicare added.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.